FluoGuide Picks Laser for Precision Cancer Therapy with FG001


FluoGuide A/S, a pioneering biotech company focused on enhancing precision in cancer surgery, has announced the selection of a cutting-edge laser system to advance the development of its innovative photothermal therapy using the FG001 compound. This strategic decision marks a significant milestone in FluoGuide’s mission to revolutionize cancer treatment by harnessing the power of light-activated targeted therapies.

The chosen laser system, known for its exceptional performance and reliability, will play a crucial role in FluoGuide’s preclinical studies and future clinical trials. By leveraging the laser’s advanced capabilities, the company aims to optimize the efficacy of FG001 in selectively targeting and destroying cancer cells while minimizing damage to healthy tissue, offering new hope for patients battling various types of solid tumors.